When reviewing the definition of R&D and the commitments from the 80s and 90s, the authors missed an opportunity to provide balance on other conditions of the agreements. June 10, 1993 letter from PMAC (now IMC) to then Industry Minister Wilson said: "achievement of these investments assumes that the international and national business and regulatory environments (including but not limited to such elements as patent protection, federal and provincial pricing regulations, approval of products for safety and efficacy, and access to provincial formularies) for the pharmaceutical industry will not undergo substantial change." The authors want to freeze the original R&D definition in amber, while everything else in Canada and globally underwent radical changes, most notably product listing agreements that picked up steam in the mid-2000s, and drive billions in rebates that effectively reduce prices down on aggregate by around 35% or even more, based on Ontario disclosures and Quebec reporting.